In Pharmacogenomics Reporter issue 1/6/2005, the article “FDA Clears Half of AmpliChip for Sale As an IVD; Rival Dx Shops Bear Down” characterized Paul Billings of LabCorp as saying “evidence, patient requests, quality, and liability concerns,” contributed to slow early P450 test demand. The text should have characterized these factors only as affecting demand.